Search - tctmd.com

Displaying 1 - 5 of 5

Sort: Relevancy | Date

No Benefit for Icosapent Ethyl, P2Y12 Inhibitors in Separate COVID-19 Trials

News Conference News AHA 2021

No Benefit for Icosapent Ethyl, P2Y12 Inhibitors in Separate COVID-19 Trials

November 15, 2021

Glucose and Beyond? Experts Debate Optimal Targets for Managing CV Risk in Diabetics

News Conference News EAS 2018

Glucose and Beyond? Experts Debate Optimal Targets for Managing CV Risk in Diabetics

Yael L. Maxwell

May 16, 2018

Is Atherosclerosis an LDL-Cholesterol or Immune Disease? The Answer May Be Both

News Conference News EAS 2017

Is Atherosclerosis an LDL-Cholesterol or Immune Disease? The Answer May Be Both

Yael L. Maxwell

April 25, 2017

News Features

Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond

December 30, 2016

News Daily News

Adding Ezetimibe to Statin Therapy Reduces Risk of First and Subsequent CV Events: IMPROVE-IT Analysis

Michael O'Riordan

January 26, 2016

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.